This study provides a novel combination immunotherapy strategy for patients with PD-L1-negative advanced non-small cell lung cancer (NSCLC), suggesting that bispecific antibodies may overcome the limitations of traditional immune checkpoint inhibitors in refractory tumors. It holds significant reference value for research into immunotherapy resistance mechanisms and the optimization of clinical regimens.
Literature Overview
The article titled 'Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial,' published in Nature Communications, systematically investigates the efficacy and safety of the PD-1/CTLA-4 bispecific antibody cadonilimab combined with chemotherapy as a first-line treatment for patients with PD-L1-negative advanced non-small cell lung cancer (NSCLC). The multicenter, single-arm study enrolled 50 patients, with the primary endpoint being the 12-month progression-free survival (PFS) rate. It also explored a molecular response prediction model based on circulating free DNA (cfDNA) methylation. The results demonstrated promising efficacy signals superior to historical controls, with manageable safety, offering a potential new therapeutic approach for this difficult-to-treat population.Background Knowledge
PD-L1-negative advanced non-small cell lung cancer (NSCLC) represents a major clinical challenge in lung cancer treatment. These patients account for nearly half of all advanced NSCLC cases but show very low response rates to single-agent PD-1/PD-L1 inhibitors. The current standard of care—PD-1 inhibitor combined with chemotherapy—delivers only limited survival benefits in this subgroup, with a median PFS of approximately 6.5 months, and some patients progress rapidly. Although dual immune blockade targeting both CTLA-4 and PD-1 has shown potential superiority over chemotherapy in some studies, its significantly increased toxicity (e.g., high rates of immune-related adverse events [irAEs] and elevated risk of treatment-related death) limits broad clinical application. Therefore, enhancing anti-tumor immune activity while controlling toxicity remains a core challenge in this field. This study addresses this issue by employing the novel bispecific antibody cadonilimab, which simultaneously targets PD-1 and CTLA-4 via a single molecule. This design theoretically enhances T-cell activation and tumor microenvironment infiltration while reducing Fc-mediated off-target toxicity. Furthermore, the study innovatively incorporates dynamic monitoring of cfDNA methylation to predict treatment response earlier than imaging assessments, providing a new tool for precision immunotherapy.
Research Methods and Experiments
The study adopted a multicenter, single-arm, phase II design (LungCadX), enrolling 50 patients with advanced NSCLC and PD-L1 TPS < 1%. All patients received cadonilimab (10 mg/kg every 3 weeks) in combination with platinum-based doublet chemotherapy (squamous: paclitaxel + carboplatin; non-squamous: pemetrexed + carboplatin) for four cycles, followed by maintenance therapy with cadonilimab plus pemetrexed. The primary endpoint was the 12-month PFS rate; secondary endpoints included ORR, DoR, OS, and safety. For biomarker analysis, whole-genome bisulfite sequencing was performed on plasma cfDNA collected at baseline (C1D1) and on day 1 of cycle 3 (C3D1) to identify differentially methylated fragments (DMFs), which were used to calculate a DMF score for molecular response assessment. Radiological evaluations followed RECIST v1.1 criteria, with longitudinal comparisons between molecular and clinical responses.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides the first phase II evidence supporting the significant efficacy of a bispecific antibody combined with chemotherapy in PD-L1-negative advanced NSCLC, filling a critical gap in precision treatment for this subgroup. Its success has prompted follow-up phase III trials (e.g., NCT05990127), which may establish a new standard of care. From a drug development perspective, cadonilimab’s molecular design exemplifies an optimized dual-immune targeting strategy—enhancing efficacy while minimizing toxicity—providing a blueprint for next-generation immunotherapies.
In terms of clinical monitoring, the application of cfDNA methylation highlights the immense potential of liquid biopsy in early prediction of immunotherapy response, reducing unnecessary treatment exposure and improving decision-making. Future validation of this molecular marker’s clinical utility in larger cohorts is warranted.
From a disease modeling standpoint, this study underscores the need for more clinically relevant model systems, such as humanized mouse models that simulate the PD-L1-negative tumor microenvironment, to investigate T-cell exhaustion and dual immune blockade mechanisms, thereby accelerating drug screening and combination strategy development.
Conclusion
This study establishes cadonilimab plus chemotherapy as a viable first-line treatment strategy for patients with PD-L1-negative advanced non-small cell lung cancer, demonstrating superior efficacy signals compared to existing regimens with manageable safety. Its core value lies not only in offering a new therapeutic option but also in validating the clinical potential of bispecific antibodies in refractory tumors, while enabling early prediction and risk stratification through dynamic cfDNA methylation monitoring. This integrated 'treatment–monitoring–prognosis' precision immunotherapy framework sets a precedent for future personalized lung cancer management. Bridging the gap from bench to bedside, the study advances the field from traditional imaging-based assessments toward molecular response-guided strategies, emphasizing the critical role of liquid biopsy in dynamic monitoring. Moreover, it highlights the importance of developing more accurate disease models—such as humanized models—to simulate PD-L1-negative microenvironments, providing essential tools for mechanistic research and drug development. Overall, this study lays a solid foundation for improving outcomes in PD-L1-negative NSCLC patients and has the potential to reshape the standard of care for this population.
